MEI Pharma is focused on the clinical development of novel therapies for the treatment of cancer. We were incorporated in Delaware in December 2000 and began trading on Nasdaq in December 2003. Daniel Gold, Ph.D., was appointed President & CEO in April 2010 and we established our headquarters in San Diego shortly thereafter. As of September 30, 2016, we had $58.9 million in cash, with no outstanding debt. Our common stock is traded on the Nasdaq Capital Market under the symbol MEIP.